The so-called Jupiter study showed that Crestor can dramatically reduce death, heart attack and stroke in patients having healthy cholesterol level but high level of a protein (C-reactive protein) associated with heart disease. The findings indicated that Crestor reduces heart attack, stroke, need for bypass or angioplasty procedures and cardiovascular death by 45 percent over less than 2 years. The Jupiter study was funded by AstraZeneca, the manufacturer for Crestor.
In a recent study, researchers from Yale University in Connecticut found that Crestor, the world’s top-selling cholesterol-lowering drug, could benefit nearly 20 percent more men and women over the age of 50 and 60 respectively in the United States. Their findings were published on January 13, 2009 in the journal Circulation: Cardiovascular Quality and Outcomes.
Looking at people with high levels of C-reactive protein, the United States researchers examined whether statins would lower their heart disease rates. Survey data from United States government were used to determine how many more people might be helped by statins, also taking into consideration of C - reactive protein levels.
The prevailing guidelines used by United States doctors indicate about 58 percent of men age 50 and older and women 60 and older, or 34 million people, would benefit from taking statins to reduce heart attack and stroke risk.
Finding from the study indicated that another 19 percent of men and women in those age groups or 11 million people should be taking the drugs. This means that 77 percent of Americans in those age groups or 45 million people should take the drugs
If the result of the study were correct, the majority of people would be recommended to take statin. Nevertheless, the researchers are not prepared to advocate such an expansion of existing guidelines on who should take statin. Instead, they felt that it is important to implement a more in-depth study of further implication that also includes cost-analysis to help future decision-making processes on the preventive measure for the population as a whole.
In a recent study, researchers from Yale University in Connecticut found that Crestor, the world’s top-selling cholesterol-lowering drug, could benefit nearly 20 percent more men and women over the age of 50 and 60 respectively in the United States. Their findings were published on January 13, 2009 in the journal Circulation: Cardiovascular Quality and Outcomes.
Looking at people with high levels of C-reactive protein, the United States researchers examined whether statins would lower their heart disease rates. Survey data from United States government were used to determine how many more people might be helped by statins, also taking into consideration of C - reactive protein levels.
The prevailing guidelines used by United States doctors indicate about 58 percent of men age 50 and older and women 60 and older, or 34 million people, would benefit from taking statins to reduce heart attack and stroke risk.
Finding from the study indicated that another 19 percent of men and women in those age groups or 11 million people should be taking the drugs. This means that 77 percent of Americans in those age groups or 45 million people should take the drugs
If the result of the study were correct, the majority of people would be recommended to take statin. Nevertheless, the researchers are not prepared to advocate such an expansion of existing guidelines on who should take statin. Instead, they felt that it is important to implement a more in-depth study of further implication that also includes cost-analysis to help future decision-making processes on the preventive measure for the population as a whole.
No comments:
Post a Comment